Picture of Veracyte logo

VCYT — Veracyte News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Veracyte Inc expected to post a loss of 18 cents a share - Earnings Preview

* Veracyte Inc  VCYT.OQ   VCYT.O  is expected to show a rise
in
quarterly revenue when it reports  results on May 7 for the
period ending March 31 2024
    * The South San Francisco California-based  company is
expected to
report a 13.3% increase in revenue to $93.37 million from $82.42
million a year ago, according to the mean estimate from 8
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Veracyte Inc is for a
loss
of 18 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Veracyte
Inc is
$32.50​, above​ its last closing price of $20.35. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.08       -0.09      -0.39     Missed  -317.9
 Sep. 30 2023  -0.14       -0.15      -0.41     Missed  -179.6
 Jan. 1 0001   -0.15       -0.15      -0.12     Beat    21.4​
 Mar. 31 2023  -0.15       -0.13      -0.11     Beat    17.8
 ​​Dec.        -0.15       -0.15      -0.05     Beat    67
 31 2022                                                
 Sep. 30 2022  -0.24       -0.25      -0.12     Beat    51.7​
 Jun. 30 2022  -0.22       -0.22      -0.13     Beat    40.5
 Mar. 31 2022  -0.24       -0.24      -0.20     Beat    15.9
 This summary was machine generated May 4 at 01:34 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Veracyte

See all news